Nabi Biophama (NABI) Receives $2.5M Milestone Payment
More News related to NABI
- Nabi Biopharmaceuticals (NABI) Receives Scientific Advice On NicVAX From the European Medicines Agency
- Nabi Biopharmaceuticals Receives Scientific Advice On NicVAX(r) From the European Medicines Agency
- Nabi Biopharmaceuticals to Present At Noble Financial's Fifth Annual Equity Conference
- Nabi Biopharmaceuticals (NABI) Announces Withdrawal of Biotest's Indemnification Claim
- Nabi Biopharmaceuticals Announces Withdrawal of Biotest's Indemnification Claim
Nabi Biopharmaceuticals (Nasdaq: NABI) has received a $2.5 million payment from Fresenius USA Manufacturing, Inc. for the successful completion of another milestone under the agreement governing the Company's 2006 sale of PhosLo and the product's related assets to Fresenius for a total consideration of up to $150 million.
This milestone payment was contingent on publication of information related to the CARE-2 (Calcium Acetate Renagel Evaluation-2) Study.
Related Categories
FDAStocks Mentioned
-0.12Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
